{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:20:55Z","timestamp":1792797655304,"version":"4.5.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brazilian Journal of Otorhinolaryngology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.bjorl.2024.101394","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T13:03:08Z","timestamp":1706619788000},"page":"101394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps \u2012 2024 update"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-2320","authenticated-orcid":false,"given":"Wilma T.","family":"Anselmo-Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Tamashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Roithmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa R.P.","family":"Dinarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio B.","family":"Piltcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel M.","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Fornazieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago F.P.","family":"Bezerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo L.L.","family":"Dolci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o F.","family":"Mello Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus M.","family":"Lessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Voegels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo M.","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulalia","family":"Sakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana C.P.","family":"Valera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjorl.2024.101394_bib0005","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope."},{"key":"10.1016\/j.bjorl.2024.101394_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1177\/0194599820965233","article-title":"Targeted molecular therapies in allergy and rhinology","volume":"164","author":"Damask","year":"2021","journal-title":"Otolaryngol Head Neck Surg."},{"key":"10.1016\/j.bjorl.2024.101394_bib0020","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1604","article-title":"Type 2 immunity: expanding our view","volume":"3","author":"Lloyd","year":"2018","journal-title":"Sci Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0025","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoto.2020.1453","article-title":"Contemporary classification of chronic rhinosinusitis beyond polyps vs no polyps: a review","volume":"146","author":"Grayson","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"10.1016\/j.bjorl.2024.101394_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"10.1016\/j.bjorl.2024.101394_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/alr.22454","article-title":"Central compartment atopic disease: prevalence of allergy and asthma compared with other subtypes of chronic rhinosinusitis with nasal polyps","volume":"10","author":"Marcus","year":"2020","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.alit.2019.05.001","article-title":"Aspirin-exacerbated respiratory disease (AERD): current understanding of AERD","volume":"68","author":"Taniguchi","year":"2019","journal-title":"Allergol Int."},{"key":"10.1016\/j.bjorl.2024.101394_bib0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/019459989411100508","article-title":"Diagnosis of allergic fungal sinusitis","volume":"111","author":"Bent","year":"1994","journal-title":"Otolaryngol Head Neck Surg."},{"key":"10.1016\/j.bjorl.2024.101394_bib0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0065","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.bjorl.2024.101394_bib0070","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.1780330807","article-title":"The American College of Rheumatology 1990 criteria for the classification of Wegener\u2019s granulomatosis","volume":"33","author":"Leavitt","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bjorl.2024.101394_bib0075","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2017.03.006","article-title":"Biologics and biomarkers for asthma, urticaria, and nasal polyposis","volume":"139","author":"Casale","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0080","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.anai.2019.07.004","article-title":"A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps","volume":"123","author":"Codispoti","year":"2019","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00151829-200403030-00006","article-title":"Omalizumab: a review of its use in the management of allergic asthma","volume":"3","author":"Bang","year":"2004","journal-title":"Treat Respir Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/1945892418814768","article-title":"Biologic agents for the treatment of chronic rhinosinusitis with nasal polyps","volume":"33","author":"Kartush","year":"2019","journal-title":"Am J Rhinol Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0095","unstructured":"Xolair\u00ae (omalizumabe). Portal Novartis. 2021. https:\/\/portal.novartis.com.br\/medicamentos\/xolair\/. [Accessed 08 December 2023]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-017-0219-4","article-title":"Asthma biomarkers in the age of biologics","volume":"13","author":"Kim","year":"2017","journal-title":"Allergy Asthma Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00405-019-05650-y","article-title":"Omalizumab versus intranasal steroids in the post-operative management of patients with allergic fungal rhinosinusitis","volume":"277","author":"Mostafa","year":"2020","journal-title":"Eur Arch Otorhinolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.09.034","article-title":"Omalizumab reduces cysteinyl leukotriene and 9\u03b1,11\u03b2-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease","volume":"137","author":"Hayashi","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.aller.2012.02.005","article-title":"Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease","volume":"41","author":"Aksu","year":"2013","journal-title":"Allergol Immunopathol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0125","first-page":"448","article-title":"Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease","volume":"20","author":"Bobolea","year":"2010","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0130","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaci.2015.10.010","article-title":"Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis","volume":"136","author":"Bachert","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0145","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1177\/0003489417731782","article-title":"Anti-IgE and Anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysis","volume":"126","author":"Rivero","year":"2017","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4193\/Rhin17.156","article-title":"Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review","volume":"56","author":"Tsetsos","year":"2018","journal-title":"Rhinology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13643-015-0157-5","article-title":"Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review","volume":"4","author":"Hong","year":"2015","journal-title":"Syst Rev."},{"key":"10.1016\/j.bjorl.2024.101394_bib0160","first-page":"473","article-title":"Effectiveness of omalizumab in the treatment of chronic rhinosinusitis with nasal polyps: systematic review","volume":"3","author":"Santos","year":"2014","journal-title":"Eur Sci J."},{"key":"10.1016\/j.bjorl.2024.101394_bib0165","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: A POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0180","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s11882-023-01106-w","article-title":"Omalizumab treatment in uncontrolled asthma and CRSwNP patients, with previous endoscopic sinus surgery, to improve quality of life and endoscopic outcomes: a Two-Year Real-Life Study","volume":"23","author":"Maza-Solano","year":"2023","journal-title":"Curr Allergy Asthma Rep."},{"key":"10.1016\/j.bjorl.2024.101394_bib0185","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jaip.2017.04.024","article-title":"Biotherapeutics in chronic rhinosinusitis with and without nasal polyps","volume":"5","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2014.03.010","article-title":"Omalizumab in asthma: an update on recent developments","volume":"2","author":"Humbert","year":"2014","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0195","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE monoclonal antibody (Omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0200","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.amjoto.2015.05.008","article-title":"Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma","volume":"36","author":"Gan","year":"2015","journal-title":"Am J Otolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.02.007","article-title":"Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab","volume":"134","author":"Long","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0210","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1182\/blood.V79.12.3101.bloodjournal79123101","article-title":"Interleukin-5, eosinophils, and disease","volume":"79","author":"Sanderson","year":"1992","journal-title":"Blood."},{"key":"10.1016\/j.bjorl.2024.101394_bib0215","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1034\/j.1398-9995.2003.00110.x","article-title":"Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis","volume":"58","author":"Gevaert","year":"2003","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0225","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.4049\/jimmunol.158.8.3902","article-title":"Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia","volume":"158","author":"Simon","year":"1997","journal-title":"J Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0230","unstructured":"Nucala (mepolizumab) Label FDA. Fda.gov. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125526Orig1s000Lbl.pdf. [Accessed December 08 2023]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0235","unstructured":"Cinqair (reslizumab) Label FDA. Fda.gov. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. [Accessed December 08 2023]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0240","unstructured":"Fasenra (benralizumab). Fda.gov. 2017. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2017\/fasenra-benralizumab-receives-us-fda-approval-for-severe-uncontrolled-eosinophilic-asthma-14112017.html. [Accessed December 08 2023]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0245","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.bjorl.2024.101394_bib0250","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0255","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet."},{"key":"10.1016\/j.bjorl.2024.101394_bib0260","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.bjorl.2024.101394_bib0265","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J."},{"key":"10.1016\/j.bjorl.2024.101394_bib0270","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0275","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cea.14112","article-title":"Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: a systematic review and meta-analysis","volume":"52","author":"Charles","year":"2022","journal-title":"Clin Exp Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0280","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaci.2006.05.031","article-title":"Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps","volume":"118","author":"Gevaert","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.17116\/otorino20218602143","article-title":"Impact of reslizumab on the course of chronic rhinosinusitis in patients with eosinophilic asthma","volume":"86","author":"Boiko","year":"2021","journal-title":"Vestn Otorinolaringol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0295","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0305","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0194599820939964","article-title":"Role of biologics in chronic rhinosinusitis with nasal polyposis: state of the art review","volume":"164","author":"Kim","year":"2021","journal-title":"Otolaryngol Head Neck Surg."},{"key":"10.1016\/j.bjorl.2024.101394_bib0310","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2023.08.015","article-title":"Mepolizumab reduces systemic corticosteroid use in chronic rhinosinusitis with nasal polyps","volume":"11","author":"Chupp","year":"2023","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0320","article-title":"Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: impact of comorbidity and sinus surgery","author":"Silver","year":"2023","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/biomedicines11020485","article-title":"Real-life effectiveness of mepolizumab in refractory chronic rhinosinusitis with nasal polyps","volume":"11","author":"Dom\u00ednguez-Sosa","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.bjorl.2024.101394_bib0330","unstructured":"United States Food and Drug Administration. Dupixent Prescribing Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf [Accessed November 30 2020]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0335","unstructured":"European Medicines Agency. Dupixent Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent. [Accessed November 30 2020]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0340","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria Consultas Anvisa Medicamentos Dupixent. https:\/\/consultas.anvisa.gov.br\/#\/medicamentos\/25351189487201920\/?nomeProduto=dupixent. [Accessed November 30 2020]."},{"key":"10.1016\/j.bjorl.2024.101394_bib0345","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.201506-377AW","article-title":"The role of type 2 inflammation in the pathogenesis of asthma exacerbations","volume":"12","author":"Dunican","year":"2015","journal-title":"Ann Am Thorac Soc."},{"key":"10.1016\/j.bjorl.2024.101394_bib0350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18176\/jiaci.0254","article-title":"Dupilumab: a new paradigm for the treatment of allergic diseases","volume":"28","author":"Sastre","year":"2018","journal-title":"J Investig Allergol Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0355","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/00034894231176334","article-title":"Effect of Dupilumab on type 2 biomarkers in chronic rhinosinusitis with nasal polyps: SINUS-52 study results","volume":"132","author":"Bachert","year":"2023","journal-title":"Ann Otol Rhinol Laryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0360","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0365","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet."},{"key":"10.1016\/j.bjorl.2024.101394_bib0370","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.anai.2018.08.005","article-title":"Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma","volume":"122","author":"Corren","year":"2019","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0375","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0380","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of Dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0385","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty Asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate Dupilumab efficacy\/safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther."},{"key":"10.1016\/j.bjorl.2024.101394_bib0390","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0400","article-title":"Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study","author":"Bacharier","year":"2023","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0405","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bjorl.2016.03.001","article-title":"Innovative therapeutic targets in chronic sinusitis with nasal polyps","volume":"82","author":"Bachert","year":"2016","journal-title":"Braz J Otorhinolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0410","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous Dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA."},{"key":"10.1016\/j.bjorl.2024.101394_bib0415","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.bjorl.2024.101394_bib0420","first-page":"10","article-title":"Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP","volume":"58","author":"Bachert","year":"2020","journal-title":"Rhinology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0425","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/all.13685","article-title":"Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis","volume":"74","author":"Jonstam","year":"2019","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.12.324","article-title":"Dupilumab reduces blood, urine, and nasal biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the Phase 3 SINUS-52 trial","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.03.023","article-title":"Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma","volume":"7","author":"Bachert","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0445","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","article-title":"Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis","volume":"44","author":"Peters","year":"2023","journal-title":"Allergy Asthma Proc."},{"key":"10.1016\/j.bjorl.2024.101394_bib0450","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0460","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2020","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0465","article-title":"Biologics for chronic rhinosinusitis","volume":"2","author":"Chong","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.bjorl.2024.101394_bib0470","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.anai.2020.07.014","article-title":"Dupilumab use in recalcitrant allergic fungal rhinosinusitis","volume":"125","author":"Lo","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0475","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/all.15134","article-title":"Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"77","author":"van der Lans","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0480","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1945892420961969","article-title":"Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease","volume":"35","author":"Mustafa","year":"2021","journal-title":"Am J Rhinol Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0485","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0490","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/alr.23059","article-title":"A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis","volume":"13","author":"Miglani","year":"2023","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0495","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0500","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost utility analysis of Dupilumab versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"131","author":"Scangas","year":"2021","journal-title":"Laryngoscope."},{"key":"10.1016\/j.bjorl.2024.101394_bib0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0510","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/19458924221112211","article-title":"Efficacy and safety of Dupilumab versus Omalizumab in chronic rhinosinusitis with nasal polyps and asthma: EVEREST trial design","volume":"36","author":"De Prado Gomez","year":"2022","journal-title":"Am J Rhinol Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0515","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0520","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1111\/all.15507","article-title":"Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease","volume":"77","author":"Xu","year":"2022","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0530","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0535","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.jaip.2023.04.033","article-title":"Nonsteroidal Anti-inflammatory Drug (NSAID) tolerance after biological therapy in patients with NSAID-Exacerbated Respiratory Disease: a randomized comparative trial","volume":"11","author":"S\u00e1nchez","year":"2023","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0540","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00085-2022","article-title":"AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps","volume":"8","author":"Siddiqui","year":"2022","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.bjorl.2024.101394_bib0545","article-title":"Optimizing the timing of biologic and surgical therapy for patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP)","author":"Garvey","year":"2023","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0550","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/all.15796","article-title":"Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months","volume":"78","author":"van der Lans","year":"2023","journal-title":"Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0555","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0560","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000534545","article-title":"Characterizing adverse events of biologic treatment of T2 disease: a disproportionality analysis of the FDA adverse event reporting system","volume":"85","author":"Stack","year":"2023","journal-title":"ORL J Otorhinolaryngol Relat Spec."},{"key":"10.1016\/j.bjorl.2024.101394_bib0565","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0570","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/cpdd.775","article-title":"A Phase 1, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tezepelumab in healthy japanese men","volume":"9","author":"Sakamoto","year":"2020","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10.1016\/j.bjorl.2024.101394_bib0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S286036","article-title":"Tezepelumab Reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY Phase 2b study","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0580","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0585","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2023.08.015","article-title":"Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma (NAVIGATOR)","volume":"131","author":"Pavord","year":"2023","journal-title":"Ann Allergy Asthma Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0595","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/JAA.S378062","article-title":"Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis","volume":"15","author":"Zoumot","year":"2022","journal-title":"J Asthma Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0600","doi-asserted-by":"crossref","first-page":"20905","DOI":"10.1038\/s41598-022-24763-9","article-title":"Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis","volume":"12","author":"Shaban Abdelgalil","year":"2022","journal-title":"Sci Rep."},{"key":"10.1016\/j.bjorl.2024.101394_bib0605","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0610","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2217\/imt-2023-0109","article-title":"Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies","volume":"15","author":"Corren","year":"2023","journal-title":"Immunotherapy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0615","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11882-023-01085-y","article-title":"Effects of Tezepelumab on quality of life of patients with moderate-to-severe, uncontrolled asthma: systematic review and meta-analysis","volume":"23","author":"Chagas","year":"2023","journal-title":"Curr Allergy Asthma Rep."},{"key":"10.1016\/j.bjorl.2024.101394_bib0620","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/JAA.S288260","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the Phase 2b PATHWAY study","volume":"14","author":"Emson","year":"2021","journal-title":"J Asthma Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0625","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.04.040","article-title":"Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype","volume":"146","author":"Delemarre","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0640","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/19458924231154061","article-title":"New concepts in Barrier dysfunction in CRSwNP and emerging roles of tezepelumab and dupilumab","volume":"37","author":"Chiang","year":"2023","journal-title":"Am J Rhinol Allergy."},{"key":"10.1016\/j.bjorl.2024.101394_bib0645","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/CS20190281","article-title":"New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis","volume":"137","author":"Striz","year":"2023","journal-title":"Clin Sci."},{"key":"10.1016\/j.bjorl.2024.101394_bib0650","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0655","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/ACI.0000000000000875","article-title":"Biologics for eosinophilic granulomatosis with polyangiitis","volume":"23","author":"Caminati","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0660","first-page":"9","article-title":"Real-world characteristics of \u201csuper-responders\u201d to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis","volume":"30","author":"Portacci","year":"2023","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.bjorl.2024.101394_bib0665","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.bjorl.2024.101394_bib0670","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-Term Rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0675","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/key117","article-title":"Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients","volume":"58","author":"Pu\u00e9chal","year":"2019","journal-title":"Rheumatology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0680","series-title":"Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical effectiveness, cost-effectiveness, and guidelines [Internet]","author":"Ho","year":"2017"},{"key":"10.1016\/j.bjorl.2024.101394_bib0685","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4078\/jrd.2022.0002","article-title":"Management of antineutrophil cytoplasmic antibody-associated vasculitis: a review of recent guidelines","volume":"30","author":"Ahn","year":"2023","journal-title":"J Rheum Dis."},{"key":"10.1016\/j.bjorl.2024.101394_bib0690","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003082","article-title":"Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis","volume":"9","author":"Schirmer","year":"2023","journal-title":"RMD Open."},{"key":"10.1016\/j.bjorl.2024.101394_bib0695","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.bjorl.2024.101394_bib0700","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bjorl.2021.03.003","article-title":"Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil","volume":"88","author":"Anselmo-Lima","year":"2022","journal-title":"Braz J Otorhinolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0705","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/chemse\/bjg061","article-title":"Ratings of overall olfactory function","volume":"28","author":"Landis","year":"2003","journal-title":"Chem Senses."},{"key":"10.1016\/j.bjorl.2024.101394_bib0710","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1007\/s00405-019-05565-8","article-title":"Measuring olfaction instead of asking: it is more than luxury! Eur","volume":"277","author":"Landis","year":"2020","journal-title":"Arch. Otorhinolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0715","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00405-019-05414-8","article-title":"Whose nose does not know? Demographical characterization of people unaware of anosmia","volume":"276","author":"Oleszkiewicz","year":"2019","journal-title":"Eur Arch Otorhinolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0720","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/chemse\/bju068","article-title":"Development of normative data for the Brazilian adaptation of the University of Pennsylvania Smell Identification Test","volume":"40","author":"Fornazieri","year":"2015","journal-title":"Chem Senses."},{"key":"10.1016\/j.bjorl.2024.101394_bib0725","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bjorl.2020.09.013","article-title":"Validation of the Connecticut olfactory test (CCCRC) adapted to Brazil","volume":"88","author":"Fen\u00f3lio","year":"2022","journal-title":"Braz J Otorhinolaryngol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0730","first-page":"435","article-title":"Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps","volume":"60","author":"Haxel","year":"2022","journal-title":"Rhinology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0735","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21293","article-title":"Predictors of prognosis in patients with olfactory disturbance","volume":"63","author":"London","year":"2008","journal-title":"Ann Neurol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0740","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneur.1997.00550210061014","article-title":"Olfactory dysfunction in patients with head trauma","volume":"54","author":"Doty","year":"1997","journal-title":"Arch Neurol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0745","article-title":"Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0750","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/jpm12081215","article-title":"Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP","volume":"12","author":"Cantone","year":"2022","journal-title":"J Pers Med."},{"key":"10.1016\/j.bjorl.2024.101394_bib0755","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"10.1016\/j.bjorl.2024.101394_bib0765","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/alr.22992","article-title":"The digital scent device as a new concept for olfactory assessment","volume":"12","author":"Nakanishi","year":"2022","journal-title":"Int Forum Allergy Rhinol."},{"key":"10.1016\/j.bjorl.2024.101394_bib0770","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4193\/Rhino15.072","article-title":"Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments","volume":"54","author":"Toma","year":"2016","journal-title":"Rhinology."},{"key":"10.1016\/j.bjorl.2024.101394_bib0775","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40463-023-00657-2","article-title":"Remission: does it already exist in chronic rhinosinusitis with nasal polyposis?","volume":"52","author":"Chan","year":"2023","journal-title":"J Otolaryngol Head Neck Surg."},{"key":"10.1016\/j.bjorl.2024.101394_bib0780","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"2023 GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir Med."}],"container-title":["Brazilian Journal of Otorhinolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1808869424000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1808869424000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:41:45Z","timestamp":1716277305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1808869424000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1808869424000090"],"URL":"https:\/\/doi.org\/10.1016\/j.bjorl.2024.101394","relation":{},"ISSN":["1808-8694"],"issn-type":[{"value":"1808-8694","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps \u2012 2024 update","name":"articletitle","label":"Article Title"},{"value":"Brazilian Journal of Otorhinolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjorl.2024.101394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Associa\u00e7\u00e3o Brasileira de Otorrinolaringologia e Cirurgia C\u00e9rvico-Facial. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101394"}}